多基因韧性评分可调节精神分裂症遗传风险
研究基于Resilience Project发现罕见变异可抵抗孟德尔疾病及复杂疾病保护等位基因,提出存在促进精神分裂症等高遗传度多基因疾病韧性的遗传变异。研究建立流程识别具有较高精神分裂症多基因风险但未患病个体,与风险匹配的精神分裂症病例对比,生成首个「多基因韧性评分」,代表与风险位点不同的变异对精神分裂症抵抗的加性贡献。该评分源自精神病基因组学联盟数据,并在三个独立样本中重复验证。
要点
- 多基因韧性评分代表与风险位点正交的变异对精神分裂症抵抗的加性贡献。
- 评分在精神病基因组学联盟数据中构建,并在三个独立样本中重复验证。
- 该框架可推广至其他复杂遗传疾病寻找韧性变异。
核心结论
- 多基因韧性评分可调节精神分裂症遗传风险,代表与风险位点不同的变异对疾病抵抗的加性贡献。
研究设计与样本
- 研究基于Resilience Project发现,建立流程识别具有较高精神分裂症多基因风险但未患病个体,并与风险匹配的精神分裂症病例对比。
- 韧性评分源自精神病基因组学联盟数据,并在三个独立样本中重复验证。
主要发现
- 研究生成首个已知「多基因韧性评分」,代表与风险位点不同的变异对精神分裂症抵抗的加性贡献。
- 该评分在三个独立样本中重复验证。
关键数值与推荐
- 韧性评分源自精神病基因组学联盟数据,并在三个独立样本中重复验证。
临床怎么用
- 该框架可推广至其他复杂遗传疾病寻找韧性变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Based on the discovery by the Resilience Project (Chen R. et al. Nat Biotechnol 34:531-538, 2016) of rare variants that confer resistance to Mendelian disease, and protective alleles for some complex diseases, we posited the existence of genetic variants that promote resilience to highly heritable polygenic disorders1,0 such as schizophrenia. Resilience has been traditionally viewed as a psychological construct, although our use of the term resilience refers to a different construct that directly relates to the Resilience Project, namely: heritable variation that promotes resistance to disease by reducing the penetrance of risk loci, wherein resilience and risk loci operate orthogonal to one another. In this study, we established a procedure to identify unaffected individuals with relatively high polygenic risk for schizophrenia, and contrasted them with risk-matched schizophrenia cases to generate the first known "polygenic resilience score" that represents the additive contributions to SZ resistance by variants that are distinct from risk loci. The resilience score was derived from data compiled by the Psychiatric Genomics Consortium, and replicated in three independent samples. This work establishes a generalizable framework for finding resilience variants for any complex, heritable disorder.
引用
- Hess JL, Tylee DS, Mattheisen M, et al. A polygenic resilience score moderates the genetic risk for schizophrenia. Mol Psychiatry. 2019. PMID: 31492941. doi:10.1038/s41380-019-0463-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。